1244 Stock Overview
A biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
3D Medicines Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.02 |
| 52 Week High | HK$9.90 |
| 52 Week Low | HK$1.92 |
| Beta | 0 |
| 11 Month Change | -21.09% |
| 3 Month Change | -21.71% |
| 1 Year Change | -77.05% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.58% |
Recent News & Updates
Benign Growth For 3D Medicines Inc. (HKG:1244) Underpins Stock's 26% Plummet
Aug 20
3D Medicines Inc. (HKG:1244) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Jul 05Recent updates
Shareholder Returns
| 1244 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -6.0% | 1.5% | 0.4% |
| 1Y | -77.0% | -11.2% | 12.0% |
Return vs Industry: 1244 underperformed the Hong Kong Biotechs industry which returned -11.2% over the past year.
Return vs Market: 1244 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 1244 volatility | |
|---|---|
| 1244 Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1244's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1244's weekly volatility has increased from 11% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 193 | John Gong | www.3d-medicines.com |
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the Mainland China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in Phase II clinical trials G/GEJ and TMB-H advanced cancer, EC, HCC,CRC, NSCLC, microsatellite satble CRC, and dMMR advanced sold tumors.
3D Medicines Inc. Fundamentals Summary
| 1244 fundamental statistics | |
|---|---|
| Market cap | HK$519.49m |
| Earnings (TTM) | -HK$483.33m |
| Revenue (TTM) | HK$525.35m |
0.9x
P/S Ratio-1.0x
P/E RatioIs 1244 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1244 income statement (TTM) | |
|---|---|
| Revenue | CN¥488.82m |
| Cost of Revenue | CN¥81.63m |
| Gross Profit | CN¥407.19m |
| Other Expenses | CN¥856.91m |
| Earnings | -CN¥449.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 83.30% |
| Net Profit Margin | -92.00% |
| Debt/Equity Ratio | 29.7% |
How did 1244 perform over the long term?
See historical performance and comparison